What does this study add?
AHCL therapy improved mean HbA
from 7.5% to 7.0%.
Almost twice as many patients achieved an HbA
≤7.0% with AHCL therapy vs. baseline.
More participants achieved a TIR
This further increased for all groups at the basal target set point of 100 mg/dL.
There were no events of diabetic ketoacidosis, severe hypoglycemia during the study phase, serious or unanticipated adverse device effects.